Levosimendan and its metabolite OR-1896 elicit KATP channel-dependent dilation in resistance arteries in vivo

Pharmacological Reports

Volumn 65, Issue 5, 2013, Pages 1304-1310

  Gödény, Ildikó ^a   Pollesello, Piero ^b   Édes, István ^a   Papp, Zoltán ^a   Bagi, Zsolt ^c,d  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b ORION CORPORATION   (Finland)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Cremaster muscle; Intravital microscopy; KATP channels; Levosimendan; OR 1896; Vasodilation

Indexed keywords

ADENOSINE TRIPHOSPHATE; GLIBENCLAMIDE; LEVOSIMENDAN; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; PINACIDIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIOLE; ARTERY DIAMETER; ARTERY DILATATION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CREMASTER MUSCLE; DRUG EFFECT; IN VIVO STUDY; MALE; NONHUMAN; RAT; VIDEO MICROSCOPY;

ACETAMIDES; ANIMALS; ARTERIOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDRAZONES; KATP CHANNELS; MALE; MICROSCOPY, VIDEO; MUSCLE, SMOOTH; POTASSIUM CHANNEL BLOCKERS; PYRIDAZINES; RATS; RATS, WISTAR; VASCULAR RESISTANCE; VASODILATION; VASODILATOR AGENTS;

EID: 84894178423     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)71488-9     Document Type: Article

References (30)

1. Akar F, Manavbasi Y, Parlar AI, Ulus AT, Katircioglu SF: The gender differences in the relaxation to levosimendan of human internal mammary artery. Cardiovasc Drugs Ther, 2007, 21, 331-338. (Pubitemid 47598926)
2. Ambrus N, Szolnoky J, Pollesello P, Kun A, Varro A, Papp JG, Pataricza J: Prolonged antispasmodic effect in isolated radial artery graft and pronounced platelet inhibition induced by the inodilator drug, levosimendan. Basic Clin Pharmacol Toxicol, 2012, 110, 269-274.
3. Banfor PN, Preusser LC, Campbell TJ, Marsh KC, Polakowski JS, Reinhart GA, Cox BF, Fryer RM: Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am J Physiol Heart Circ Physiol, 2008, 294, H238-248.
4. De Witt BJ, Ibrahim IN, Bayer E, Fields AM, Richards TA, Banister RE, Kaye AD: An analysis of responses to levosimendan in the pulmonary vascular bed of the cat. Anesth Analg, 2002, 94, 1427-1433. (Pubitemid 34556617)
5. Eksert B, Usta C: Role of potassium channels in the relaxant effect of levosimendan in guinea pig tracheal preparations. Pharmacol Rep, 2009, 61, 275-280.
6. Erdei N, Papp Z, Pollesello P, Edes I, Bagi Z: The levosimendan metabolite OR-1896 elicits vasodilation by activating the KATP and BKCa channels in rat isolated arterioles. Br J Pharmacol, 2006, 148, 696-702. (Pubitemid 43993060)
7. Hohn J, Pataricza J, Petri A, Toth GK, Balogh A, Varro A, Papp JG: Levosimendan interacts with potassium channel blockers in human saphenous veins. Basic Clin Pharmacol Toxicol, 2004, 94, 271-273. (Pubitemid 38954893)
8. Kaheinen P, Pollesello P, Levijoki J, Haikala H: Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol, 2001, 37, 367-374. (Pubitemid 32240418)
9. Kêdzior K, Szczepañska R, Kociæ I: Contribution of NO, ATP-sensitive K+ channels and prostaglandins to adenosine receptor agonists-induced relaxation of the rat tail artery. Pharmacol Rep, 2009, 61, 330-334.
10. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ: Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol, 2002, 42, 43-51. (Pubitemid 34038369)
11. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ: Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther, 2002, 40, 465-471. (Pubitemid 35153452)
12. Kivikko M, Lehtonen L, Colucci WS: Sustained hemodynamic effects of intravenous levosimendan. Circulation, 2003, 107, 81-86. (Pubitemid 36070937)
13. Landoni G, Mizzi A, Biondi-Zoccai G, Bignami E, Prati P, Ajello V, Marino G et al.: Levosimendan reduces mortality in critically ill patients. A meta-analysis of randomized controlled studies. Minerva Anestesiol, 2010, 76, 276-286.
14. Loeb AL, Godeny I, Longnecker DE: Functional evidence for inward-rectifier potassium channels in rat cremaster muscle arterioles. Microvasc Res, 2000, 59, 1-6. (Pubitemid 30073132)
15. Michaels AD, McKeown B, Kostal M, Vakharia KT, Jordan MV, Gerber IL, Foster E, Chatterjee K: Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation, 2005, 111, 1504-1509. (Pubitemid 40470645)
16. Michelakis ED, Reeve HL, Huang JM, Tolarova S, Nelson DP, Weir EK, Archer SL: Potassium channel diversity in vascular smooth muscle cells. Can J Physiol Pharmacol, 1997, 75, 889-897. (Pubitemid 27451808)
17. Papp Z, Van Der Velden J, Borbely A, Edes I, Stienen GJ: Effects of Ca2+-sensitizers in permeabilized cardiac myocytes from donor and end-stage failing human hearts. J Muscle Res Cell Motil, 2004, 25, 219-224. (Pubitemid 44961624)
18. Pataricza J, Hohn J, Petri A, Balogh A, Papp JG: Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol, 2000, 52, 213-217. (Pubitemid 30125304)
19. Pataricza J, Krassoi I, Hohn J, Kun A, Papp JG: Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther, 2003, 17, 115-121. (Pubitemid 37174684)
20. Sandell EP, Hayha M, Antila S, Heikkinen P, Ottoila P, Lehtonen LA, Pentikainen PJ: Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J Cardiovasc Pharmacol, 1995, 26, Suppl 1, S57-62. (Pubitemid 26064555)
21. Sato S, Talukder MA, Sugawara H, Sawada H, Endoh M: Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. J Mol Cell Cardiol, 1998, 30, 1115-1128. (Pubitemid 28327780)
22. Segreti JA, Marsh KC, Polakowski JS, Fryer RM: Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl- 6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4,5- dihydropyridazin-3(2H)-one], dobutamine, and milrinone: comparative effects on peripheral resistance, cardiac output, dP/dt, pulse rate, and blood pressure. J Pharmacol Exp Ther, 2008, 325, 331-340. (Pubitemid 351439154)
23. Sun X, Cao K, Yang G, Huang Y, Hanna ST, Wang R: Selective expression of Kir6.1 protein in different vascular and non-vascular tissues. Biochem Pharmacol, 2004, 67, 147-156. (Pubitemid 37518542)
24. Szilagyi S, Pollesello P, Levijoki J, Kaheinen P, Haikala H, Edes I, Papp Z: The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol, 2004, 486, 67-74. (Pubitemid 38130162)
25. Takahashi R, Endoh M: Effects of OR-1896, a metabolite of levosimendan, on force of contraction and Ca2+ transients under acidotic condition in aequorin-loaded canine ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol, 2002, 366, 440-448. (Pubitemid 35244907)
26. Takahashi R, Talukder MA, Endoh M: Effects of OR-1896, an active metabolite of levosimendan, on contractile force and aequorin light transients in intact rabbit ventricular myocardium. J Cardiovasc Pharmacol, 2000, 36, 118-125. (Pubitemid 30419131)
27. Takahashi R, Talukder MA, Endoh M: Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium. Eur J Pharmacol, 2000, 400, 103-112. (Pubitemid 30412115)
28. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N: Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol, 1997, 333, 249-259. (Pubitemid 27387398)
29. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N: The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. J Pharmacol Exp Ther, 1997, 283, 375-383. (Pubitemid 27438984)
30. Zangrillo A, Biondi-Zoccai G, Mizzi A, Bruno G, Bignami E, Gerli C, De Santis V et al.: Levosimendan reduces cardiac troponin release after cardiac surgery: a meta-analysis of randomized controlled studies. J Cardiothorac Vasc Anesth, 2009, 23, 474-478.